Gene therapy represents 'new paradigm' for treatment of hematologic disorders
Researchers in hematology have long believed that gene therapy may provide a pathway to more effectively treat chronic genetic hematologic disorders, with the potential for functional cures in certain cases.
Healio - Tue, 09 Feb 2016 23:37



4 Emerging Growth Biotech Names for the Next Generation
I believe there is the potential to demonstrate the same kind of efficacy in solid tumor settings as has historically been the case in hematological malignancies. TLSR: Ram, there's one other important issue with regard to market uptake of new therapies.
Equities.com - Thu, 11 Feb 2016 02:41

Biogen and Target ALS Foundation Announce $20 Million Corporate Funding Challenge
Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is ...
FierceBiotech - Wed, 10 Feb 2016 04:56

Insider Sale: Alfred Sandrock Sold 852 Shares of Biogen Inc (NASDAQ:BIIB)
The Firm is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. It has 16.44 P/E ratio. The Firm develops, makes and markets products designed for the treatment of multiple ...
fdanewsalert.com - Wed, 10 Feb 2016 14:07

Risk factors and outcome of graft failure after HLA matched and mismatched ...
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763. | PubMed ...
Nature.com - Mon, 08 Feb 2016 06:42

Ligand Reports Fourth Quarter and Full Year 2015 Financial Results
At the American Society of Hematology (ASH) 57th annual meeting, the National Institutes of Health presented data from a single-center Phase 2 study with Promacta, showing that more than one-third of patients with severe aplastic anemia achieved ...
Business Wire (press release) - Wed, 10 Feb 2016 13:00

Spark Therapeutics Inc (NASDAQ:ONCE)'s Company Shares Decreased 25.53% After ...
The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based ...
fdanewsalert.com - Wed, 10 Feb 2016 11:07

Invivoscribe Reports Long-Term Collaboration to Develop Immuno-Oncology Tests ...
Invivoscribe® Technologies, Inc., a global company that provides international access to personalized molecular diagnostics, today announces it has signed a long-term strategic collaboration agreement with Thermo Fisher Scientific to develop multiple ...
Investing News Network (press release) (registration) (blog) - Wed, 10 Feb 2016 10:00

Invivoscribe Announces Long-Term Collaboration to Develop Immuno-Oncology ...
SYS-CON Media (press release) - Wed, 10 Feb 2016 04:56


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014